Paradigm Shift in Defining Asthma Variants in 2020- GuestPostWeb

Asthma is a chronic respiratory disease that is on the rise. 10% of Americans and 25% of people in Europe are suffering from the debilitating factors of asthma. The impact of this disease on society and a nation's economy is staggering. The individual suffering is a given considering missing school, missing work on account of caring for a young person. The cost of medication is on the rise and the health care systems in most westernized countries are under increasing pressure to control costs.

The EAACI (European Academy of Allergy and Clinical Immunology) and the EPA (Environmental Protection Agency) in the United States are on the same page when they both agree that controlling environmental factors is the best form of prevention of asthma.

This is not an article on what causes asthma for the simple reason nobody knows what causes this dreaded disease. What is definitely known is that environmental asthma triggers are all around us and the only way to confront it is via education and awareness.

Understanding types of asthma has seen a paradigm shift in the understanding as endotype asthma has entered the lexicon. Endotype refers to a sub text of a condition. It is different from phenotype which is an observation of traits in a disease. In endotype the disease is defined by the symptoms which by its very nature asthma fit the condition.

Earlier there was little knowledge of these sub conditions which limited the understanding of the causes of asthmatic attacks. With new hypothesis such as asthma endotype there is environmental correlation as well as genetic understanding.

Generally endotype is a combination disease as a symptom, as a state and as a process. Asthma qualifies on all three of these conditions that allow specificity of identifying the trigger.This new criteria of compartmenting the subtype of asthma has led to research in clinical study of design and drug delivery that can target existing conditions and introduce newer therapies.

EACCI has embarked in leading the movement to bring awareness to not only patients but also to all stakeholders such as Governments, research and development organizations, pharmaceutical stakeholders among others. Their aim is to bring global consciousness and consensus for diagnosis and therapy via prevention. The complexities of asthmatic disease has not been conducive in finding an effective cure but EACCI believes that managing this disease through controlling the environment factors can greatly reduce the incidence of people suffering from this dreadful disease.

Make no mistake that the financial factors for the poor are a very big burden to carry. In most cases it is out of reach as people make do with what they have.

Post a Comment

Previous Post Next Post